AN2 Therapeutics, Inc. (ANTX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 10.55M | 9.32M | 10.04M | 7.22M | 11.54M | 8.6M | 14.01M | 15.88M | 18.3M | 18.82M | 18.18M | 16.6M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.81M | 2.44M | 3.04M | 4.02M | 3.85M | 3.21M | 3.48M | 3.73M | 3.64M | 3.9M | 3.75M | 3.06M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 6.74M | 6.88M | 7M | 3.2M | 7.69M | 5.4M | 8.29M | 12.15M | 14.65M | 14.92M | 14.43M | 13.54M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -9K | 1000K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -10.55M | -9.32M | -10.04M | -7.22M | -11.54M | -8.6M | -14.01M | -15.88M | -18.3M | -18.82M | -18.18M | -16.6M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 8.55% | -8.35% | 28.36% | 54.56% | 36.94% | 54.3% | 22.92% | 4.34% | -14.07% | -50.81% | -54.46% | -60.66% |
| EBITDA | -10.03M | -10M | -9.35M | -7.22M | -11.54M | 9K | -11.77M | 9.53M | -18.3M | -16.9M | 0 | -16.6M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 13.08% | -111244.44% | 20.54% | -175.73% | 36.94% | 100.05% | - | 157.39% | - | -35.44% | 100% | -60.66% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 8.61M | 0 | 25.41M | 0 | 0 | 18.18M | 0 |
| EBIT | -10.03M | -10M | -9.35M | -7.22M | -11.54M | -8.61M | -11.77M | -15.88M | -18.3M | -16.9M | -18.18M | -16.6M |
| Net Interest Income | 523K | 605K | 687K | 754K | 888K | 0 | 0 | 0 | 1.68M | 0 | 0 | 0 |
| Interest Income | 523K | 605K | 687K | 754K | 888K | 0 | 0 | 0 | 1.68M | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 523K | 606K | 687K | 754K | 888K | 1.08M | 1.27M | 1.45M | 1.68M | 1.92M | 1.47M | 797K |
| Pretax Income | -10.03M | -8.71M | -9.35M | -6.46M | -10.65M | -7.52M | -12.75M | -14.44M | -16.62M | -16.9M | -16.71M | -15.8M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.03M | -8.71M | -9.35M | -6.46M | -10.65M | -7.52M | -12.75M | -14.44M | -16.62M | -16.9M | -16.71M | -15.8M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 5.83% | -15.79% | 26.63% | 55.23% | 35.91% | 55.49% | 23.7% | 8.66% | -8.44% | -42.7% | -47.34% | -56.17% |
| Net Income (Continuing) | -10.03M | -8.71M | -9.35M | -6.46M | -10.65M | -7.52M | -12.75M | -14.44M | -16.62M | -16.9M | -16.71M | -15.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.29 | -0.29 | -0.31 | -0.21 | -0.35 | -0.25 | -0.43 | -0.48 | -0.56 | -0.57 | -0.65 | -0.81 |
| EPS Growth % | 17.14% | -16% | 27.91% | 56.25% | 37.5% | 56.14% | 33.85% | 40.74% | 25.33% | 13.64% | -16.07% | -55.77% |
| EPS (Basic) | -0.29 | -0.29 | -0.31 | -0.21 | -0.35 | -0.25 | -0.43 | -0.48 | -0.56 | -0.57 | -0.65 | -0.81 |
| Diluted Shares Outstanding | 34.06M | 30.22M | 30.28M | 30.17M | 30.05M | 29.88M | 29.84M | 29.82M | 29.76M | 29.73M | 25.64M | 19.5M |
| Basic Shares Outstanding | 34.06M | 30.22M | 30.28M | 30.17M | 30.05M | 29.88M | 29.84M | 29.82M | 29.76M | 29.73M | 25.64M | 19.5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |